Abstract: The compound [9‐3H]SCH23390 [R‐(+)‐8‐chloro‐2,3,4,5‐tetrahydro‐3‐methyl‐5‐phenyl‐1H‐3‐benzazepine‐7‐ol] was synthesized, and the binding of this purportedly selective antagonist of D1 3,4‐dihydroxyphenylethylamine (dopamine) receptors was characterized. The regional distribution of high‐affinity, specific [3H]SCH23390 binding sites in the rat brain correlated well with levels of endogenous dopamine. Receptor densities were greatest in corpus striatum, nucleus accumbens, and olfactory tubercle; intermediate levels were found in several limbic and cortical areas, whereas few sites were detectable in cerebellum, brainstem, and olfactory bulb. Specific binding in caudate‐putamen was found to be both temperature‐ and pH‐dependent, with optima at 25–30°C and pH 7.8–8.0. Scatchard or Woolf analyses of binding in caudate‐putamen suggest that most of the sites are either of a single class or of classes with similar characteristics (KD= 0.7 ± 0.1 nM; Bmax= 347 ± 35 fmol/mg of protein). Both dopamine and cis‐flupenthixol altered the slope but not the intercept of lines generated by Scatchard analysis, suggesting a competitive mode of inhibition of [3H]SCH23390 binding. Competition for binding by dopamine or the D1 agonist SKF38393 was inhibited by guanine nucleotides, whereas GTP had little effect on the competition for binding by the antagonist cis‐flupenthixol. The competition for [3H]SCH23390 binding sites by dopamine was much more sensitive to GTP than was competition for [3H]spiperone binding. These data support the hypotheses that [3H]SCH23390 binds to recognition sites that differ from those previously described using other radiolabeled dopamine antagonists and that these sites have the characteristics expected of dopamine receptors.
|Original language||English (US)|
|Number of pages||11|
|Journal||Journal of neurochemistry|
|State||Published - Nov 1985|
All Science Journal Classification (ASJC) codes
- Cellular and Molecular Neuroscience